干扰素高表型：结直肠癌治疗中由生物标志物驱动的突破。
The IFN-high phenotype: A biomarker-driven breakthrough in colorectal cancer treatment.
作者信息
Allonsius Lize, Kelecom Luca, Laoui Damya
机构信息
Lab of Dendritic Cell Biology and Cancer Immunotherapy, VIB Center for Inflammation Research, Brussels, Belgium; Lab of Cellular and Molecular Immunology, Brussels Center for Immunology, Vrije Universiteit Brussel, Brussels, Belgium.
Lab of Dendritic Cell Biology and Cancer Immunotherapy, VIB Center for Inflammation Research, Brussels, Belgium; Lab of Cellular and Molecular Immunology, Brussels Center for Immunology, Vrije Universiteit Brussel, Brussels, Belgium.
出版信息
Cell Rep Med. 2025 Mar 18;6(3):102025. doi: 10.1016/j.xcrm.2025.102025.
Patient stratification is crucial for improving immunotherapy effectiveness. Acha-Sagredo et al. identified an interferon (IFN)-high immunophenotype and CD74 overexpression as predictors for immunotherapy response in colorectal cancer (CRC). This signature, involving cytotoxic T cells and antigen-presenting macrophages, was found in both mismatch repair-deficient and -proficient CRCs. CD74 overexpression could serve as a biomarker, enabling personalized CRC treatment.
患者分层对于提高免疫治疗效果至关重要。阿查-萨格雷多等人确定了一种高干扰素（IFN）免疫表型和CD74过表达作为结直肠癌（CRC）免疫治疗反应的预测指标。这种涉及细胞毒性T细胞和抗原呈递巨噬细胞的特征在错配修复缺陷型和 proficient型CRC中均有发现。CD74过表达可作为一种生物标志物，实现CRC的个性化治疗。
Zotero 插件